Hematopoietic Stem Cell Transplantation Market - By Therapy (Allogenic, Autologous), Indication (Lymphoproliferative Disorder, Leukemia), Application (Bone Marrow & Stem Cell Transplant), Distribution Channel, End-user, Global Forecast (2023-2032)

Hematopoietic Stem Cell Transplantation Market - By Therapy (Allogenic, Autologous), Indication (Lymphoproliferative Disorder, Leukemia), Application (Bone Marrow & Stem Cell Transplant), Distribution Channel, End-user, Global Forecast (2023-2032)

Hematopoietic Stem Cell Transplantation Market Size

Hematopoietic Stem Cell Transplantation Market size was valued to be USD 2.6 billion in 2022 and is expected to reach USD 6.2 billion in 2032 with a CAGR of 9.3% by 2032 due to the increasing incidence of leukemia, rising success rate of transplantation, and technological advancements in the transplantation procedures.
 

Hematopoietic stem cells (HSCs) are multipotent precursors that have self-renewal capacity and the ability to regenerate all the different cell types that comprise the blood-forming system. Hematopoietic stem cell transplantation (HSCT) includes the intravenous infusion of hematopoietic stem cells to reestablish blood cell production in patients whose immune system or bone marrow are damaged. This technique is used to treat numerous malignant and non-malignant diseases such as leukemia, lymphoma, sickle cell disease, and congenital neutropenia.
 

COVID-19 Impact

To stop the spread of COVID-19, numerous countries implemented countrywide lockdowns. Similar difficulties were encountered by healthcare businesses maintaining their supply chain operations in various countries throughout the world. As COVID cases declined, the strict restrictions were eased, increasing number of visits to hospitals, and allowing the patients to undergo treatment.
 

On the other hand, the COVID-19 pandemic resulted in increase of leukemia and lymphoma. According to data released by the Leukemia & Lymphoma Society (LLS), 61,090 persons were estimated to receive a leukemia diagnosis in 2021.The increase in incidence of leukemia along with the increase in awareness about the therapies and various technological advancements in stem cell therapy drives the development. Numerous government initiatives to develop the stem cell transplantation centers have an even greater influence on market dynamics.
 

Hematopoietic Stem Cell Transplantation Driving Factors

The rising prevalence of haematological disorders, increasing healthcare expenditure, the growing elderly population with weakened immune systems making them more prone to diseases, and rise in the research and development activities are fuelling the evolution of the hematopoietic stem cell transplantation market.
 

Ongoing advancements in HSCT techniques, including improved conditioning regimens, increasing availability of donors, better matching of donors and recipients, and enhanced post-transplant care, have increased the success rates of transplantation procedures. Additionally, the use of cord blood as a source of stem cells for HSCT has been increasing. Umbilical cord blood contains hematopoietic stem cells and is an alternative source of stem cells for patients who lack suitable adult donors.
 

Hematopoietic Stem Cell Transplantation Market Analysis

Based on therapy type, the hematopoietic stem cell transplantation market is divided into allogeneic transplant therapy and autologous transplant therapy. The autologous transplant therapy segment held the largest market share of 57.6% in 2022. Autologous transplantation eliminates the need to find a compatible donor, which can be challenging in allogeneic transplantation. This reduces the time and resources required for donor search and facilitates a quicker transplantation process. Moreover, autologous HSCT allows for the use of higher doses of chemotherapy or radiation, which can be more effective in killing cancer cells or suppressing the immune system in autoimmune diseases. The subsequent infusion of the patient's own stem cells helps restore the bone marrow and immune system.
 

Based on indication type, the hematopoietic stem cell transplantation market is divided into lymphoproliferative disorders, leukemia, non-malignant disorders, and other indications. The leukemia segment is further subdivided into acute myeloid leukemia, acute lymphatic leukemia, myelodysplastic syndrome, and other leukemia. The leukemia segment held the largest market share of 72% in 2022. Leukemia is one of the most common cancers worldwide affecting significant number of people. The high incidence of leukemia drives the demand for effective treatments, including HSCT, especially in cases where other therapies have been less successful. The lymphoproliferative disorders segment is further subdivided into non-hodgkin lymphoma, hodgkin lymphoma, plasma cell disorders, and other lymphoproliferative disorders.
 

Based on application type, the hematopoietic stem cell transplantation market is divided into bone marrow stem cell transplant, peripheral blood stem cell transplant, and cord blood transplant. Bone marrow stem cell transplantation offers the potential for a cure in certain haematological disorders, especially in cases where standard treatments have been ineffective, or disease relapse has occurred. Its ability to provide long-term disease-free survival makes it a critical treatment option for eligible patients.
 

The bone marrow stem cell transplantation is the treatment of choice for several haematological conditions, including leukemia, lymphoma, multiple myeloma, and aplastic anemia.
 

Based on end-user, the hematopoietic stem cell transplantation market is classified into hospitals, specialty clinics, and other end-users. The hospitals segment held dominant market share of around 52.5% in 2022 and is expected to grow at a significant pace of 9.1% by 2032. Hospitals are equipped with comprehensive healthcare facilities, including specialized units for bone marrow transplantation. These facilities enable hospitals to offer a full range of services required for the preparation, transplantation, and post-transplant care of HSCT patients.
 

North America hematopoietic stem cell transplantation marketis expected to reach USD 2.2 billion in 2032 with a CAGR of 9.1% by 2032. North America boasts a well-developed and advanced healthcare infrastructure, including specialized transplant centers and comprehensive cancer centers. These facilities provide access to state-of-the-art technology, expertise, and resources necessary for successful HSCT procedures.
 

Moreover, North America has a relatively high incidence of haematological disorders, such as leukemia, lymphoma, and multiple myeloma. According to American Cancer Society, it is estimated that there will be 59,610 new cases of leukemia in 2023.
 

Hematopoietic Stem Cell Transplantation Market Share

The well known, established, prominent players in hematopoietic stem cell transplantation market are

• Pluristem Therapeutics Inc.
• Sanofi
• Taiga Biotechnologies, Inc
• CellGenix GmbH
• Novartis AG
• Regen Biopharma Inc.
• Kiadis Pharma
• Marker Therapeutics, Inc.
• Escape Therapeutics, Inc.
• GlaxoSmithKline plc
• Merck KGaA
• Bluebird Bio, Inc.
• Talaris Therapeutics.

Hematopoietic Stem Cell Transplantation Market Industry News

• In May 2022, Priothera was granted permission by the US Food and Drug Administration to begin a Phase 2b/3 research with mocravimod (a synthetic, sphingosine 1-phosphate receptor (S1PR) modulator) in acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplant (HSCT).

• In December 2021, the United States Food and Drug Administration authorized the procedure to treat acute graft-versus-host disease (GVHD) in patients 2 years of age and older receiving hematopoietic stem cell transplants from matched or single-HLA-mismatched unrelated donors.

The global hematopoietic stem cell transplantation market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

By Therapy type

• Allogenic transplant therapy
• Autologous transplant therapy

By Indication

• Lymphoproliferative disorders 
• Non-Hodgkin lymphoma
• Hodgkin lymphoma
• Plasma cell disorders
• Other lymphoproliferative disorders 
• Leukemia
• Acute myeloid leukemia
• Acute lymphatic leukemia
• Myelodysplastic syndrome
• Other leukemia types 
• Nonmalignant disorders
• Bone marrow failure
• Hemoglobinopathies
• Other nonmalignant disorders

By Application

• Bone marrow stem cell transplant
• Peripheral blood stem cell transplant
• Cord blood transplant

By End-user

• Hospitals
• Specialty centers
• Other end-users

The above information is provided for the following regions and countries

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin Americ 
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa 
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa